Matteo Tozzi, MD, vascular surgeon and professor of vascular surgery at Università dell’Insubria in Italy, and Frans L. Moll, MD, PhD, professor emeritus of vascular surgery at the University Medical Center Utrecht in The Netherlands, provided insights on the progress of the aXess trial in an interview with Healio Nephrology.
For more on Xeltis’ aXess, the first restorative synthetic hemodialysis access graft, on the unmet research needs that the aXess trial is aiming to address and on current and potential findings, you can read the full article here.
Xeltis initiated a European first-in-human trial on aXess in patients with kidney failure or advanced kidney disease requiring dialysis. A number of patients have already been successfully implanted as part of the trial to date.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.